Who Paid My Doc
Melissa Bear
Pediatric Hematology-Oncology Indianapolis, IN Medical Doctor
NPI 1336200989 CMS profile 1113020
705 Riley Hospital Dr, Roc 4340, Indianapolis, IN 46202
General payments
$26,181
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$352,314
Through program year 2024, Melissa Bear of Indianapolis, IN is reported in the CMS Open Payments database as having received $26,181 across 14 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $352,314 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 86th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $63 | 1 | |
| 2023 | General | $14,683 | 5 | |
| 2022 | General | $11,311 | 7 | |
| 2021 | General | $125 | 1 |
Beside peers
- Melissa Bear
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Melissa Bear were reported at $0. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Melissa Bear | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $184 | $69–$2,094 | $163 |
| 2020 | $0 | $220 | $37–$3,941 | $114 |
| 2021 | $125 | $366 | $63–$4,909 | $132 |
| 2022 | $11,311 | $181 | $66–$2,775 | $149 |
| 2023 | $14,683 | $175 | $62–$2,600 | $160 |
| 2024 | $63 | $227 | $66–$2,992 | $164 |
| 2025 | $0 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Indiana
Amy Shapiro
Pediatric Hematology-Oncology · Indianapolis, IN
Sanjay Ahuja
Pediatric Hematology-Oncology · Indianapolis, IN
Bassem Razzouk
Pediatric Hematology-Oncology · Indianapolis, IN
Steven Rhodes
Pediatric Hematology-Oncology · Indianapolis, IN
Kyle Davis
Pediatric Hematology-Oncology · Indianapolis, IN
Seethal Jacob
Pediatric Hematology-Oncology · Indianapolis, IN
Related records
Pediatric Hematology-Oncology in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.